Company intelligence / Profile preview

Oncopeptides AB

Ownership: Private
Employees: ~79
Development stage: Commercial

Overview

Oncopeptides has commercialized its lead product, melflufen (branded as Pepaxti in Europe), for relapsed/refractory multiple myeloma. The drug has demonstrated effectiveness and tolerability in real-world studies among heavily pretreated patients. The company’s next-generation PDC candidate OPD5 recently had its FDA clinical hold lifted and will enter new clinical trials. Additional assets from the SPiKE platform are advancing toward first-in-human studies

Therapeutic areas: Oncology
Modalities: Peptide Drug Conjugates (PDC)Small Polypeptide-based Innate Killer Engagers (SPiKE)
Industry: Biotech

Drug pipeline

7 assets

Hepzato

Approved

6 more assets in the full pipeline.

Partnerships

No major pharma partnerships publicly disclosed as of May 2025; company open to future partnerships to support development of OPD5 and other candidates

Beyond the preview

Go deeper on Oncopeptides AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncopeptides AB.